A report on ‘Lateral Flow Assays Market’, compiled by Persistence Market Research, provides a lucid analysis regarding the values and trends existing in the current business scenario. The study also offers a brief summary of market valuation, market size, and regional outlook and profit estimations of the industry. Furthermore, the report examines the competitive sphere and growth strategies of leading players in the Lateral Flow Assays Market.
Request Sample: https://www.persistencemarketresearch.com/samples/18613
With the advent of lateral flow assays, the testing has been brought away from the laboratory and closer to the patient. One of the major benefit of later flow assay testing is that it leads to early diagnosis, treatment and monitoring of health conditions.
The healthcare industry has entered the era of rapid diagnostics, in which test results are almost instantaneous and accurate. Moreover, complex and costly equipment is not used in the lateral flow assays. Lateral flow assays uses immunoassay technology through a combination of antibodies colored nanoparticles and nitrocellulose membranes to present test results that can be visually interpreted. One of the most popular example of lateral flow assay testing is the pregnancy test.
The global lateral flow assays market is slated to touch a value of about US$ 7,900 Mn in the year 2022 and grow at a robust CAGR during the assessment period.
Request For Methodology: https://www.persistencemarketresearch.com/methodology/18613
The report has also included the profiles of some of the leading companies in the lateral flow assays market like Siemens Healthineers, Danaher Corporation, Thermo Fisher Scientific, Inc., Dickinson and Company, Abbott Laboratories, Hologic Inc., Alere Inc., Johnson and Johnson, Becton, PerkinElmer, Inc., bioMerieux S.A, QIAGEN N.V. and Bio-Rad Laboratories Inc.